title: Interferon-alpha does not cause significant cardiac dysfunction in patients with chronic active hepatitis.
abstract: The cardiac adverse effects of interferon (INF) treatment have been reported recently in various clinical trials of INF. In this study, the cardiac effects of recombinant INF-alpha treatment were evaluated prospectively in a group of patients with chronic active viral hepatitis (CAH). Sixteen patients with CAH type B, 14 patients with CAH type C and one patients with CAH type D were included in this study, and 4.5, 3 and 9 MU of recombinant INF-alpha-2a was administrated three times a week to these patients, respectively. The durations of treatment were 6 months for CAH type B and C, and 12 months for type D. The cardiac status of all patients was evaluated and monitored with a detailed medical history, physical examination, electrocardiography (ECG), telecardiography, echocardiography and heart rate variability tests at the beginning of the study and at the first and sixth months of INF therapy and also 6 months after ceasing the therapy. The clinical evaluation of patients before the treatment revealed that three had hypertension, one had a past medical history of myocardial infarction, one had a prosthetic mitral valve replacement and another had left hemiblock in her ECG record. No significant changes and adverse effects were detected in clinical examination and cardiovascular tests of all patients, either in pre-existing cardiovascular diseases, during therapy and after stopping the treatment. The cardiac adverse effects of INF reported in previous studies are questionable and we conclude that it can be used safely in CAH patients. Therefore, it should be kept in mind that fever and tachycardia may occur during the first and second weeks of INF therapy and patients with high risk for cardiac disease should be monitored closely in this period of treatment.
authors.affiliation: Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Kadayifci
authors.forename: K
authors.initials: K
authors.lastname: Aytemir
authors.forename: M
authors.initials: M
authors.lastname: Arslan
authors.forename: S
authors.initials: S
authors.lastname: Aksoyek
authors.forename: B
authors.initials: B
authors.lastname: Sivri
authors.forename: G
authors.initials: G
authors.lastname: Kabakci
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000209:etiology*; D002319:Cardiovascular System / Q000187:drug effects*; D004452:Echocardiography; D005260:Female; D006525:Hepatitis, Viral, Human / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011994:Recombinant Proteins; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins